Stay updated with breaking news from Ericl Simpson. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis More than twice as many
Combination lebrikizumab and topical corticosteroids outperformed topical corticosteroids alone in the treatment of atopic dermatitis in adolescents and adults, according to a phase 3 study.“Currently, emollients and topical corticosteroids (TCS) are mainstay treatments for mild AD. In moderate to severe AD, the addition of systemic therapy and/or phototherapy is recommended,” Eric L.
The ADhere study compared responses at 16 weeks to the investigational biologic and topical corticosteroids vs topical corticosteroids alone in adults and adolescents with moderate to severe AD.
With no unexpected signals, a recent review of tralokinumab safety out to 1 year found no unexpected signals and provided some information about potential advantages of flexible dosing.
Researchers found no significant relationship between median week 16 dupilumab levels and 1-year clinical responses.